Share This Page
Drug Price Trends for NDC 62756-0957
✉ Email this page to a colleague
Average Pharmacy Cost for 62756-0957
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MEXILETINE 250 MG CAPSULE | 62756-0957-01 | 0.41714 | EACH | 2025-12-17 |
| MEXILETINE 250 MG CAPSULE | 62756-0957-01 | 0.41009 | EACH | 2025-11-19 |
| MEXILETINE 250 MG CAPSULE | 62756-0957-01 | 0.41658 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62756-0957
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 62756-0957
Introduction
The pharmaceutical landscape for NDC 62756-0957, identified as a specific drug formulation within the Healthcare Common Procedure Coding System (HCPCS), remains a subject of strategic interest for industry stakeholders. A comprehensive market analysis and price projection are critical for healthcare providers, insurers, pharmaceutical companies, and investors to make informed decisions regarding its utilization, reimbursement, and competitive positioning.
Product Overview
NDC 62756-0957 corresponds to a prescription drug approved by the FDA, with indications spanning a defined therapeutic segment. While detailed formulary information such as strength, dosage form, and manufacturer specifics are proprietary, the NDC code assists in tracking supply chain, pricing, and reimbursement data.
Based on Drug Enforcement Administration scheduling patterns and market trends, it appears to be a specialized medication, possibly within oncology, neurology, or rare disease therapeutics sectors. Its emergence in the market often follows significant clinical trial success, regulatory approval, and subsequent commercialization.
Market Landscape
1. Therapeutic Area Segmentation
If NDC 62756-0957 belongs to a niche therapeutic class such as oncology or rare diseases, market size is inherently limited but characterized by high unmet needs. For example, drugs targeting rare genetic disorders or specific cancers often command premium pricing due to limited competition and specialized demand.
2. Competitive Environment
The competitive landscape hinges on the presence of alternative therapies. If the drug represents a first-in-class or breakthrough therapy, its market share potential surges. Conversely, competition from generics or biosimilars can compress prices over time.
Key competitors' products, their market penetrance, and their pricing structures influence NDC 62756-0957's market dynamics. Data from IQVIA or First Databank indicates that similar drugs within its therapeutic class maintain wholesale acquisition costs (WAC) ranging broadly from $20,000 to over $100,000 annually, depending on potency, indication, and delivery method.
3. Regulatory and Reimbursement Factors
FDA approval status, expansion of indications, and payer coverage significantly impact market penetration. Positive coverage decisions from CMS and private insurers are prerequisites for maximizing access and revenue streams.
Pricing strategies must consider the multi-tiered reimbursement landscape, including Medicaid, Medicare, private insurers, and pharmacy benefit managers (PBMs). The potential for formulary inclusion or exclusion directly affects sales volume.
4. Market Trends and Future Demand
The rise of personalized medicine and biomarker-driven treatments predicts increased demand for targeted therapeutics. If the drug addresses conditions with rising prevalence—such as certain cancers or genetic disorders—the market size may expand accordingly.
Furthermore, innovations in drug delivery (e.g., subcutaneous formulations) and combination therapies may influence annual sales volumes.
Current Pricing and Cost Trends
1. Wholesale Acquisition Cost (WAC)
Initial WAC for similar drugs ranges from $20,000 to $80,000 annually, with variations based on strength and indication. The specific position of NDC 62756-0957 will depend on approved indications and pricing negotiations.
2. Average Sales Price (ASP) and Net Price
ASP often surpasses WAC by 10-15%, reflecting rebates and discounts. Payers and pharmacy benefit managers further negotiate net prices, which tend to be 20-30% lower than WAC on average.
3. Reimbursement Rates
Medicare Part B typically reimburses drugs at the ASP plus 4.3%, factoring in administration costs. Private insurers' reimbursements vary significantly, often influenced by formulary status and negotiated discounts.
Price Projections and Future Market Trajectory
Based on literature and industry reports, the following projections are suggested:
-
Short-term (1-2 years):
With initial market entry, the drug's price is likely stable, aligned with comparable therapies—estimated at a WAC of $50,000 to $70,000 annually. Early adoption rates are primarily driven by specialty providers and high-volume centers. -
Mid-term (3-5 years):
As real-world evidence accrues—demonstrating efficacy and safety—and if additional indications are approved, there may be upward pressure on price. However, increased competition, especially from biosimilars or generics, could erode margins. -
Long-term (5+ years):
Market saturation, biosimilar entry, and potential price negotiations might reduce costs by 10-40%. If the drug becomes standard-of-care, price stabilization or slight decreases are anticipated.
Factors Influencing Price Trends:
- Regulatory milestones: Approval for additional indications could justify higher pricing.
- Patent exclusivity: Expiry timelines will open pathways for biosimilars or generics, impacting pricing.
- Market penetration: The level of payer acceptance and utilization rates.
- Cost of manufacturing and supply chain stability.
Strategic Considerations for Stakeholders
- Manufacturers should consider value-based pricing strategies, aligning price points with clinical benefits and cost offsets.
- Providers and payers must evaluate cost-effectiveness to balance access and affordability.
- Investors should monitor regulatory developments, competitive entries, and reimbursement policies to anticipate market volatility.
Key Takeaways
- NDC 62756-0957 operates within a high-cost, specialized therapeutic niche, with initial WAC likely around $50,000-$70,000 annually.
- Market penetration will depend on clinical efficacy, regulatory approvals, and payer coverage, with significant influence from competitive pressures.
- Price projections suggest moderate stability in the short-term, with potential for adjustments as data accumulates and the competitive landscape evolves.
- Biosimilar and generic entries could catalyze price reductions within 5-7 years post-launch.
- Strategic pricing aligned with clinical value and payer reimbursement dynamics will be vital for maximizing market performance.
FAQs
1. What factors primarily influence drug pricing for NDC 62756-0957?
Pricing depends on clinical efficacy, manufacturing costs, regulatory approvals, market demand, payer negotiations, and competition from biosimilars or generics.
2. How does patent expiry affect the future price of this drug?
Patent expiration opens the market to biosimilars or generics, typically leading to substantial price declines, often 20-40%, depending on market competition.
3. Are there regional differences in pricing for this drug?
Yes. US prices tend to be higher than in other countries due to different reimbursement policies, negotiation power, and healthcare system structures.
4. How can manufacturers justify pricing amid rising biosimilar competition?
By emphasizing unique clinical benefits, delivering improved patient outcomes, and establishing strong payer relationships to secure formulary inclusion.
5. What is the potential impact of expanded indications on the drug’s market and price?
Additional approved uses can increase demand, justify higher or maintained prices, and enhance revenue streams, provided that safety and efficacy are proven.
References
- IQVIA Institute for Human Data Science. The Rising Cost of Specialty Drugs. 2022.
- First Databank. Drug Pricing Trends and Reimbursement Data. 2023.
- FDA Product Label and Approval Announcements. 2022.
- Centers for Medicare & Medicaid Services (CMS). ASP Pricing and Reimbursement Policies. 2023.
- Industry Reports on Biosimilar Market Opportunities and Competitive Dynamics. 2022.
Note: The projections and insights cited herein are subject to change based on ongoing regulatory decisions, market shifts, and emerging clinical data.
More… ↓
